CLGN

Across TCGA pan-cancer cohorts, CLGN mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CLGN data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher CLGN mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CLGN expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

GBM, LUAD, and PDAC are the cancer types where CLGN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.726	0.274	<.001	16	view →
LUAD	DFS	Tertile	All	0.902	0.959	.011	11	view →
PDAC	DFS	Median	All	0.630	1.000	.036	4	view →
LSCC	OS	Median	All	1.000	0.937	.012	3	view →
HNSC	DFS	Tertile	II,III,IV	0.588	0.870	.046	2	view →
CCRCC	DFS	Median	II,III,IV	0.723	0.942	.026	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CLGN–GBM (OS)

Open the GBM breakdown →